ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

HHS: Gallo Committed Scientific Misconduct In AIDS Virus Discovery

January 8, 1993

Bristol-Myers, USDA Agreement n Yew Harvest Is Near; Agencies Plan Public Briefings On Taxol

June 14, 1991

In Brief Election Results Won’t Hurt Cancer Program, May Help; Coper To Stay If Carter Wants Him

November 12, 1976

IOM: No Negligence In FIAU Clinical Trial That Killed Five

March 31, 1995

In Brief: Recompetition Of Frederick Contract Flops, As Others Leave The Field To Litton-Bionetics

April 15, 1977

CTEP Drafts FDA Approval Guidelines

March 4, 1988